Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate
University of Wisconsin, Madison
10 participants
Mar 7, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
Eligibility
Inclusion Criteria1
- Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor
Exclusion Criteria3
- Unable to lie flat during or tolerate PET/CT or SPECT/CT
- Known incompatibility to CT. SPECT, or PET scans
- Unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
SPECT/CT will be performed after first cycle of Lutathera® treatment
PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
Standard of care administration of radioactive drug for PET/CT
Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06122610